Form 4: CytomX Therapeutics Director Mani Mohindru Acquires Stock Options

Director Mani Mohindru of CytomX Therapeutics acquired stock options exercisable for 38,000 shares of common stock on May 15, 2024.

Summary

• On May 15, 2024, Mani Mohindru, a director of CytomX Therapeutics, Inc., acquired stock options for 38,000 shares of common stock at an exercise price of $1.98.
• The options vest on the earlier of May 15, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director.
• Following the transaction, Mohindru directly owns options exercisable for 38,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continued service as a director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates